Indication-specific pricing for cancer drugs

JAMA. 2014 Oct 22-29;312(16):1629-30. doi: 10.1001/jama.2014.13235.
No abstract available

MeSH terms

  • Antineoplastic Agents / economics*
  • Cost Control
  • Drug Costs*
  • Europe
  • Health Policy
  • United States

Substances

  • Antineoplastic Agents